Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pyxis Oncology (PYXS) EBITDA Margin (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed EBITDA Margin for 2 consecutive years, with 164.18% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin changed N/A to 164.18% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 575.39% through Dec 2025, down 9711.0% year-over-year, with the annual reading at 575.39% for FY2025, 9711.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 164.18% at Pyxis Oncology, up from 652.77% in the prior quarter.
  • The five-year high for EBITDA Margin was 20.93% in Q1 2024, with the low at 652.77% in Q2 2025.